All GSK articles
-
BusinessNitrosamine contamination withdrawals spread to new drugs
After ranitidine recalls, EU regulators instruct companies to review all their products for potential impurities
-
News
Pilot malaria vaccination programme begins in Malawi
Mosquirix vaccine will be rolled out in Ghana and Kenya next week
-
Business
GSK and Pfizer joint venture creates new consumer healthcare giant
Enlarged GSK consumer health will have largest market share of any firm and be a leader in key countries
-
Business
Pharmaceuticals roundup 2018
Merger deals, product approvals and infrastructure changes have been overshadowed by political uncertainty, in Europe and around the world
-
Business
Cleaning up clinical trials
Campaigns to enforce complete and correct reporting of trial data are beginning to take hold
-
Business
Novartis to cut over 2000 jobs
Move exemplifies a wave of manufacturing cuts as pharma moves to more high-value, specialised medicines
-
Business
Gene therapy gathers pace
Sarah Houlton charts the evolution, challenges and opportunities of cell and gene therapy
-
News
Patrick Vallance named as UK’s next chief scientific adviser
GlaxoSmithKline’s head of R&D will take up new post in March 2018
-
Business
GSK’s shingles vaccine gets thumbs up in North America
Inoculation slated to be a blockbuster
-
Business
US to invest $160m in cancer partnership
Funds will be backed up with $55m from 11 companies to advance new cancer treatments that harness the immune system
-
-
Business
GSK stops over 30 research programmes to prioritise innovation
New boss Emma Walmsley outlines sweeping changes in order to focus on high-return drug projects
-
Opinion
(+)-Pleuromutilin
Total synthesis is sometimes the only way to explore the chemical space around a natural product
-
Business
Amplifying intelligent drug design
This year’s Chemistry World Entrepreneur of the year is Andrew Hopkins of start-up Exscientia and the University of Dundee, UK
-
Business
How do chemical firms last hundreds of years?
What distinguishes companies that thrive from others that failed?
-
Research
Drug binding simulations promise to get personal
Fast, reliable new molecular dynamic simulation methods set to speed up research are under investigation by GSK
-
News
Pharma giants commit to tackling antimicrobial resistance
Plan to tackle superbugs includes changes to manufacturing and sales incentives
-
Business
Unpicking doctor payments
Accepting even small meals from drug industry reps appears to influence doctors’ prescription rates
-
Opinion
Healing the world
Will GSK’s move towards licensing patents in developing countries, rather than rigidly defending them, improve access to medicines?
-
Business
GSK fined for stalling antidepressant generics
UK Competition and Markets Authority deems pay-for-delay deal illegal and imposes £45m in fines
